Stomach - Proton pump inhibitors

Home Chapter Home Jobs Conferences Fellowships Books

Stomach

Other non-neoplastic lesions

Proton pump inhibitors

Reviewers: Elliot Weisenberg, M.D. (see Reviewers page)
Revised: 6 August 2012, last major update August 2012
Copyright: (c) 2003-2012, PathologyOutlines.com, Inc.

General
=========================================================================

● Includes omeprazole, lansoprazole, dexlansoprazole, esomeprazole, rabeprazole
● Used to treat gastroesophageal reflux disease (GERD)
● Patients may develop G-cell and enterochromaffin cell-like hyperplasia, secondary to drug-induced achlorhydria
● Long-term therapy associated with fundic gland polyps (sessile, multiple, <1.0 cm) in 17% after 3 months, in 35% after 5 months treatment
● Polyps regress when treatment stops (Hum Pathol 2000;31:684)

Micro description
=========================================================================

● Glandular luminal dilatation with swelling and bulging of the superficial cytoplasm of parietal cells (so-called parietal cell protrusion)
● Glands lined by cells with serrated rather than a smooth border

Micro images
=========================================================================

Gastric corpus glands post-proton pump inhibitors; lumina are dilated, parietal cells show serrated surface contour

End of Stomach > Other non-neoplastic lesions > Proton pump inhibitors

This information is intended for physicians and related personnel, who understand that medical information is often imperfect, and must be interpreted in the context of a patient's clinical data using reasonable medical judgment. This website should not be used as a substitute for the advice of a licensed physician.

All information on this website is protected by copyright of PathologyOutlines.com, Inc. Information from third parties may also be protected by copyright. Please contact us at copyrightPathOut@gmail.com with any questions (click here for other contact information).